oNKo-innate Pty Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From oNKo-innate Pty Ltd
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
- Gene Therapy, Cell Therapy
Drug Discovery Tools